Gilead Sciences, Inc (NASDAQ:GILD) shares traded -4.03% lower at $88.40 on Wall Street last session.
GILD stock price is now 1.98% away from the 50-day moving average and 18.12% away from the 200-day moving average. The market capitalization of the company currently stands at $105.73B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $110, Wolfe Research recently initiated with Outperform rating for Gilead Sciences, Inc (NASDAQ: GILD). On November 14, 2024, Citigroup recently initiated its ‘Buy’ rating on the stock quoting a target price of $125, while ‘Maxim Group’ rates the stock as ‘Hold’
In other news, Mercier Johanna, Chief Commercial Officer sold 5,000 shares of the company’s stock on Nov 06 ’24. The stock was sold for $456,400 at an average price of $91.28. Upon completion of the transaction, the Chief Commercial Officer now directly owns 73,127 shares in the company, valued at $6.46 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 06 ’24, Chief Medical Officer Parsey Merdad sold 25,590 shares of the business’s stock. A total of $2,341,485 was realized by selling the stock at an average price of $91.50. This leaves the insider owning 99,599 shares of the company worth $8.8 million. A total of 0.21% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $98.90. As of last week, the company has a debt-to-equity ratio of 1.26, a current ratio of 1.26, and a quick ratio of 1.10. According to the stock market information, the enterprise value for the company is $126637899776, which is based on a 996.62 price-to-earnings ratio, a 124.58 price-to-earnings-growth ratio, and a beta of 0.19. The fifty day moving average price for GILD is $86.6828 and a two-hundred day moving average price translates $74.84185 for the stock.
The latest earnings results from Gilead Sciences, Inc (NASDAQ: GILD) was released for 2024-09-30. The net profit margin was 0.45% and return on equity was 0.62% for GILD. The company reported revenue of $7.54 billion for the quarter, compared to $7.05 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.01 percent.
